# Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis

> **NCT06962020** · — · RECRUITING · sponsor: **Xijing Hospital of Digestive Diseases** · enrollment: 400 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** first-line biologic：IFX
- **DRUG:** first-line biologic:VDZ

## Key facts

- **NCT ID:** NCT06962020
- **Lead sponsor:** Xijing Hospital of Digestive Diseases
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2025-11-20
- **Final completion:** 2025-11-20
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06962020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06962020, "Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06962020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*